September 11, 2019 / 8:00 AM / a year ago

Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

FRANKFURT, Sept 11 (Reuters) - Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation.

Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designatihere last year.

All three medicines are designed to tackle the so-called MET exon14 skipping mutation in the genetic makeup of a lung tumour, which accounts for 3% to 5% of all non-small cell lung (NSCLC) cancer cases.

Germany's Merck KGaA, which in February struck a large collaboration deal over cancer immunotherapy bintrafusp alfa with GSK, reiterated on Wednesday that it would develop tepotinib under its own steam. (Reporting by Ludwig Burger, editing by Riham Alkousaa)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below